MDACC Study No:2010-0808 ( NCT No: NCT01243944)
Title:Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor ruxolitinib tablets verSus bEst available care (The RESPONSE Trial)
Principal Investigator:Srdan Verstovsek
Treatment Agent:Ruxolitinib
Study Status:Closed
Study Description:The goal of this clinical research study is to compare INC424 (referred to from
here on as ruxolitinib) to the best available therapy when given to patients
with PV.
Hide details for General InformationGeneral Information

Disease Group:Myeloproliferative Diseases
Phase of Study:Phase III
Treatment Agents:Ruxolitinib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Incyte/Novartis Oncology
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults